Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the ...
The anti-diabetic drug phenformin may prompt stronger cancer-fighting activities than its sister compound metformin, a finding that could have major implications for current and future clinical trials ...
DURING the past five years phenethylbiguanide, more commonly known as phenformin or DBI, has proved to be a potent hypoglycemic agent. 1 Its main use has been in the control of maturity-onset diabetes ...
BOSTON - The anti-diabetic drug phenformin may prompt stronger cancer-fighting activities than its sister compound metformin, a finding that could have major implications for current and future ...
Researchers from the University of Dundee have shown that a drug previously used to treat Type II diabetes could potentially be used to protect against cancer. A study carried out by Professors ...
Dublin, March 26, 2025 (GLOBE NEWSWIRE) -- The "Phenformin (CAS 114-86-3) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...
A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results